Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Amarin Provides 2010 Year-End Review to Shareholders

January 31, 2011 By Bio-Medicine.Org

DUBLIN and MYSTIC, Conn., Jan. 31, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN
), a clinical-stage biopharmaceutical company with a focus
on cardiovascular disease, today issued a special letter to its
shareholders. The text of the letter, written by Joseph S.
Zakrzewski, Executive Chairman and Chief Executive Officer of
Amarin, follows:

Dear Shareholders:

With 2011 now underway, I am pleased to provide you with a brief
review of Amarin’s accomplishments in 2010 and an outline of our
strategy for 2011 and beyond. In summary, 2010 was a very
successful year for us, and we look forward to continued success in
the year to come.

Our Recent Accomplishments Include:

Successful top-line results from our Phase 3 MARINE trial Completed
patient randomization for our Phase 3 ANCHOR trial Strengthened
management team and board of directors Strengthened balance sheet
with additional $100M cash On track for a 2011 NDA submission

AMR101 is Positioned to Be Best-in-Class Therapy for Very
High TriglyceridesIn November 2010, we announced that AMR101,
Amarin’s lead product candidate for the treatment of patients with
very high triglycerides (>500 mg/dL), met the primary endpoint
in the Phase 3 MARINE study with highly significant reductions in
triglycerides from baseline compared to placebo at both the 4 gram
and 2 gram doses. In addition to achieving these key endpoints, the
results of this trial exceeded our expectations with no
statistically significant increase in LDL-cholesterol observed at
either dose, with triglyceride lowering that was greater in the
predefined subset of patients on statin therapy and with
encouraging results regarding prespecified markers of inflammation.
Additionally, we observed in the trial a safety profile for AMR101
similar to placebo. The endpoints for this trial were
establishe

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech